Prostate Cancer: A Journey Through Its History and Recent Developments
- PMID: 39857976
- PMCID: PMC11763992
- DOI: 10.3390/cancers17020194
Prostate Cancer: A Journey Through Its History and Recent Developments
Abstract
Prostate cancer is one of the most common diseases among men worldwide and continues to pose a serious threat to health. This review shows the history and the new developments in the management of prostate cancer, with an emphasis on a range of therapeutic approaches, such as hormone therapy, radiation therapy, surgery, and innovative targeted therapeutics. The evolution of these treatments is examined in light of clinical outcomes, patient quality of life, and emerging resistance mechanisms, such as the recently shown vitamin D-based strategies. New developments that have the potential to increase survival rates and reduce side effects are also discussed, including PARP inhibitors (PARPis), immunotherapy, and tailored medication. Additionally, the use of biomarkers and sophisticated imaging methods in therapeutic decision-making is explored, with a focus on how these tools might improve patient care. The absolute necessity for a multidisciplinary approach for improving treatment strategies is becoming more and more apparent as our understanding of the biology of prostate cancer deepens. This approach ensures that patients receive customized medicines that fit their unique profiles. Future avenues of investigation will focus on resolving issues dealing with treatment efficacy and resistance to improve treatment results, ultimately leading to disease cure for prostate cancer patients.
Keywords: hormone therapy; immunotherapy; personalized medicine; prostate cancer; radiation therapy; resistance; surgery.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
-
Emerging Biomarker-Guided Therapies in Prostate Cancer.Curr Oncol. 2022 Jul 18;29(7):5054-5076. doi: 10.3390/curroncol29070400. Curr Oncol. 2022. PMID: 35877260 Free PMC article. Review.
-
Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.J Exp Clin Cancer Res. 2024 May 15;43(1):146. doi: 10.1186/s13046-024-03065-0. J Exp Clin Cancer Res. 2024. PMID: 38750579 Free PMC article. Review.
-
Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments.Cancers (Basel). 2023 Oct 19;15(20):5047. doi: 10.3390/cancers15205047. Cancers (Basel). 2023. PMID: 37894414 Free PMC article. Review.
Cited by
-
Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials.J Endocrinol Invest. 2025 Jul;48(7):1659-1668. doi: 10.1007/s40618-025-02583-8. Epub 2025 Apr 17. J Endocrinol Invest. 2025. PMID: 40244528 Free PMC article.
-
Multiple highly methylated CpG sites as potential epigenetic markers for the diagnosis of prostate cancer.Clin Epigenetics. 2025 Jul 11;17(1):122. doi: 10.1186/s13148-025-01930-z. Clin Epigenetics. 2025. PMID: 40646603 Free PMC article.
References
-
- US Preventive Services Task Force. Grossman D.C., Curry S.J., Owens D.K., Bibbins-Domingo K., Caughey A.B., Davidson K.W., Doubeni C.A., Ebell M., Epling J.W., et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319:1901. doi: 10.1001/jama.2018.3710. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources